ArticleTherapeutic advances in infectious disease
Prevalence, molecular carbapenemase detection, and antibiotic resistance of carbapenem-resistant
Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resistance to novel antimicrobial agents among NDM-and OXA-48-producing Carbapenem-resistant Enterobacterales in Lebanon.Frontiers in cellular and infection microbiology · 2026Article
- Empiric antibiotic regimen for febrile neutropenia in cancer patients: a tertiary oncology center experience.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Objectives: We aimed to identify the prevalence and genetic characterization of CRE in addition to determining antibiotic resistance profiles and the effect of independent variables on carbapenemase gene types. Design: The study is a retrospective cross-sectional study conducted at a tertiary care hospital in East Jerusalem. Methods: Data were collected from microbiology, molecular, and infectious diseases units from May 2019 till November 2023. Non-repetitive isolates that tested positive for CRE according to the CLSI (M100, S29, 2023) and American Society for Microbiology Diagnostic Microbiology Proceedings manual were included with no age exclusion. Results: A total of 599 CRE non-repetitive isolates were included, carbapenemase detected (C-CRE detected) genes were seen in 421 isolates, while the remaining 178 isolates were carbapenemase not detected (C-CRE not detected). The most common carbapenemase gene was Conclusion: CRE is a growing problematic health issue that spotlights the urgent need for integrated, complete, and appropriate national antimicrobial stewardship and infection prevention and control programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.